Abstract
To the Editor: We appreciate the comments of Drs. Mahler and Fritzler1 in the letter to the editor regarding our article2. We will sincerely reply to the concerns raised by the authors. We acknowledge that interlaboratory differences in anticarbamylated protein (anti-CarP) ELISA are an important issue. Although we slightly modified the original method used by Shi, et al 3, the prevalence of anti-CarP antibodies in rheumatoid arthritis (RA) using our method was similar to that reported previously4. Therefore, we consider our in-house ELISA to be equivalent to those used in other laboratories. Our recent study gives a detailed protocol of our system5. We agree with the comment regarding … Address correspondence to Dr. K. Ohmura, Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto, Japan. E-mail: ohmurako{at}kuhp.kyoto-u.ac.jp
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
